You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Despite the dramatic growth in overall testing revenue, the company's core oncology testing revenue dropped significantly quarter-over-quarter.
For the quarter ended Sept. 30, the company reported $2.2 million in revenues, down from $3.3 million in Q3 of 2019 but beating the average Wall Street estimate.
The company beat the consensus Wall Street estimate on the top line but narrowly missed it on the bottom line.
In its first complete quarter as a publicly traded company, Berkeley Lights reported $18.2 million in total revenues, including $4.1 million in service revenues.
Williams v Quest/Athena struck a nerve with the genetic testing community by probing what the standard of care is and ought to be for variant classification.
A negative preliminary decision regarding reimbursement for the company's flagship colon cancer screening test in the US remains an issue for the company.
The firm said that overall cartridge volumes in Q3 were back at pre-pandemic levels, and that it is on track to achieve targeted 30 percent growth for full-year 2020.
The assay can be used to pool up to five specimens collected from individuals suspected of having COVID-19 or from asymptomatic patients.
The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.
The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.
Development revenues for the Seattle-based firm ticked up 5 percent to $15.0 million in Q3, partially offset by a 3 percent dip in sequencing revenues.
For the three months ended Sept. 30, the firm reported revenues of $1.8 million compared to $5.4 million in the same period the year before.
The Chinese company is branching out from its core genomics business to liquid biopsy cancer screening and monitoring as it eyes areas for global expansion.
The RT-PCR-based test is designed for the qualitative detection of SARS-CoV-2 nucleic acid in upper and lower respiratory specimens.
The PCR assay, which runs on the firm's Idylla platform, detects SARS-CoV-2 RNA in nasopharyngeal swabs from patients suspected to have COVID-19.
Genosity will combine its Integrated Genomic Toolkit with Israel-based Igentify's genetic counseling software, which both firms will comarket.
The company has been relentless in scaling its capabilities to offer COVID-19 testing solutions in the face of the coronavirus pandemic.
The company performed 84,067 total tests in Q3 but missed the analysts' average estimates on the top and bottom lines.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.